Objective: Major Depressive Disorder (MDD) may be a risk factor for subsequent development of irreversible dementia; however, the influence of a premorbid history of MDD on the clinical course of patients diagnosed with probable Alzheimer disease (AD) has not been fully explored.

Methods: Forty-three AD patients with mild-to-moderate cognitive impairment were screened for a life-long history of MDD with the Clinical Assessment of Depression in Dementia Scale. Twenty-two subjects had a history of MDD before onset of cognitive impairment, but none was suffering from an MDD episode at time of cognitive assessment.

Results: After controlling for age, education, duration of illness, gender, and medication status, subjects with a history of MDD had significantly lower scores, as a group, on cognitive performance tests, including the Mini-Mental State Exam, WAIS Full-Scale and Verbal Scale I.Q., and the Initiation/Perseveration subscale of the Mattis Dementia Rating Scale. These subjects also developed symptoms of dementia at a significantly earlier age than the subjects who had no premorbid history of MDD.

Conclusions: Although previous studies have shown that late-onset MDD may increase risk for subsequent dementia, the current results suggest that premorbid MDD is associated with more severe cognitive deficits during the actual course of dementia.

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ajgp.13.4.312DOI Listing

Publication Analysis

Top Keywords

history mdd
16
major depressive
8
alzheimer disease
8
mdd
8
premorbid history
8
mdd clinical
8
cognitive impairment
8
subjects history
8
dementia
6
history
5

Similar Publications

Insulin resistance (IR) has been proposed as a contributing factor to major depressive disorder (MDD), with previous studies reporting a positive correlation between triglyceride-glucose (TyG) a proxy indicator of IR and MDD. However, limited information is available regarding their longitudinal association. This study aimed to clarify the connection between TyG levels and depression risk, as well as explore its predictive potential.

View Article and Find Full Text PDF

Introduction: Psychotic depression (PD) is a highly debilitating disorder characterized by hallucinations and/or delusions accompanied by depression. A variety of neurotransmitters, hormones and corresponding receptors in the endocrine system are involved in the onset and progression of depression, and fasting blood glucose (FBG) can be an important indicator for monitoring the stability of the endocrine system. The aim of this study was to investigate the relationship between FBG and PD in a Chinese population with first-episode drug-naïve (FEDN) major depressive disorder (MDD).

View Article and Find Full Text PDF

Background: Traumatic brain injury (TBI) is associated with an increased risk of major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). We aimed to identify predictors and develop models for the prediction of depression and PTSD symptoms at 6 months post-TBI.

Methods: We analysed data from the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury study.

View Article and Find Full Text PDF

Risk and Protective Factors for the Evolution of Subthreshold Depression During Early Adolescence.

J Adolesc Health

January 2025

Laboratory of Cognitive Control and Brain Healthy, Department of Psychology, School of Public Health, Southern Medical University, Guangzhou, China; Department of Psychiatry, Zhujiang Hospital, Southern Medical University, Guangzhou, China. Electronic address:

Purpose: Subthreshold depression refers to a condition involving clinically significant depressive symptoms that fall short of meeting the diagnostic criteria for major depressive disorder (MDD). Identifying risk and protective factors associated with the progression of subthreshold depression in early life is essential for timely prevention. However, there is limited research on this topic among early adolescents.

View Article and Find Full Text PDF

Accumulating evidence supports the efficacy of (es)ketamine in the treatment of major depressive disorder (MDD), particularly treatment-resistant depression (TRD). Yet around 50% of the individuals with TRD do not respond to (es)ketamine. Elucidating predictors of response and remission could improve treatment outcomes at the individual level by defining subpopulations that are most likely to benefit from (es)ketamine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!